Peripheral Mechanism of Cancer-Induced Bone Pain

Yang, Yachen; Yang, Wei; Zhang, Ruofan; Wang, Yanqing

doi:10.1007/s12264-023-01126-6

Cited by 3 publications

(1 citation statement)

References 152 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most patients with metastatic bone cancer experience severe pain. The molecular mechanisms by which bone metastasis generates pain are only beginning to be understood ( Figure 1 ) [ 59 , 60 , 61 , 62 ]. Cancer cells create their own acidic microenvironment [ 62 , 63 , 64 ].…”

Section: Trpv1 In Cancer Pain: Molecular Mechanismsmentioning

confidence: 99%

Targeting TRPV1 for Cancer Pain Relief: Can It Work?

Szallasi

2024

Cancers

View full text Add to dashboard Cite

Chronic intractable pain affects a large proportion of cancer patients, especially those with metastatic bone disease. Blocking sensory afferents for cancer pain relief represents an attractive alternative to opioids and other drugs acting in the CNS in that sensory nerve blockers are not addictive and do not affect the mental state of the patient. A distinct subpopulation of sensory afferents expresses the capsaicin receptor TRPV1. Intrathecal resiniferatoxin, an ultrapotent capsaicin analog, ablates TRPV1-expressing nerve endings exposed to the cerebrospinal fluid, resulting in permanent analgesia in women with cervical cancer metastasis to the pelvic bone. High-dose capsaicin patches are effective pain killers in patients with chemotherapy-induced peripheral neuropathic pain. However, large gaps remain in our knowledge since the mechanisms by which cancer activates TRPV1 are essentially unknown. Most important, it is not clear whether or not sensory denervation mediated by TRPV1 agonists affects cancer progression. In a murine model of breast cancer, capsaicin desensitization was reported to accelerate progression. By contrast, desensitization mediated by resiniferatoxin was found to block melanoma growth. These observations imply that TRPV1 blockade for pain relief may be indicated for some cancers and contraindicated for others. In this review, we explore the current state of this field and compare the analgesic potential of TRPV1 antagonism and sensory afferent desensitization in cancer patients.

show abstract

Section: Trpv1 In Cancer Pain: Molecular Mechanismsmentioning

confidence: 99%

Targeting TRPV1 for Cancer Pain Relief: Can It Work?

Szallasi

2024

Cancers

View full text Add to dashboard Cite

show abstract

A simple nanoplatform of thermo-sensitive liposomes and gold nanorods to treat bone metastasis through improved chemotherapy combined with photothermal therapy

Gu,

Jiang,

Chen

et al. 2024

International Journal of Pharmaceutics: X

View full text Add to dashboard Cite

Analgesic treatment for refractory cancer pain caused by gastric cancer bone metastasis: A case report and literature review

Wang,

Jiang,

Zheng

et al. 2024

Medicine

View full text Add to dashboard Cite

Rationale: Patients with bone metastasis-associated cancer pain often experience a complex mix of pain types. Consequently, the use of multimodal combination therapy is essential. While monitoring for common adverse reactions in pain treatment, it is also crucial to be vigilant for the rare but serious serotonin syndrome. Patient concerns: A 53-year-old female with metastatic gastric cancer was hospitalized due to severe, uncontrolled thoracic and cervical pain. During the titration of her cancer pain medication, she developed serotonin syndrome. Diagnoses: He was diagnosed with refractory cancer pain and serotonin syndrome. Interventions: The complete process of cancer pain medication in a patient with gastric cancer and bone metastasis was analyzed, with a primary focus on the selection of analgesic medications, adjustment of opioid dosages, and prevention and treatment of medication-associated adverse reactions. Outcomes: The patient’s cancer pain was well controlled, with the prompt management of adverse reactions. Furthermore, by adjusting the medication regimen, intolerable adverse reactions were prevented. Lessons: In clinical settings, personalized analgesic regimens must be developed for patients with cancer pain to enhance patient compliance with medication, prevent the occurrence of severe adverse reactions, and improve the overall quality of life of patients with cancer. Healthcare professionals should pay increased attention to ADRs associated with opioid medications, whereas pharmacists should assist them in promptly identifying ADRs.

show abstract

Peripheral Mechanism of Cancer-Induced Bone Pain

Cited by 3 publications

References 152 publications

Targeting TRPV1 for Cancer Pain Relief: Can It Work?

Targeting TRPV1 for Cancer Pain Relief: Can It Work?

A simple nanoplatform of thermo-sensitive liposomes and gold nanorods to treat bone metastasis through improved chemotherapy combined with photothermal therapy

Analgesic treatment for refractory cancer pain caused by gastric cancer bone metastasis: A case report and literature review

Contact Info

Product

Resources

About